The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or ...
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. | ...
Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...
While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed ...
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse ...
-- Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene -- IFLI contributed up to $9 million to Enterome's private funding round in 2025 -- Enterome has announced a ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the 'Company'; HKEX: ...
Curcumin and milk thistle extracts reduce oxidative stress, enhance vaccine response and support intestinal integrity in ...
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...
China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results